MYGN

Myriad Genetics, Inc. (MYGN) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This filing covers the quarterly period ended March 31, 2026. Myriad Genetics, Inc. is a leading molecular diagnostics and precision medicine company operating as a single segment. The company develops and commercializes molecular tests across three primary categories: Cancer Care Continuum, Prenatal Health, and Mental Health. As of May 1, 2026, the company had 94.4 million shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 2.3% year-over-year to $200.4 million. This was driven by a 13% volume increase in the Cancer Care Continuum segment and a 7% volume increase in Mental Health, partially offset by a 12% volume decline in Prenatal Health.
• Impairment Charges: The company recorded a $5.4 million non-cash impairment charge related to goodwill and long-lived assets in the Women's Health reporting unit. This was triggered by a sustained decline in share price and market capitalization.
• Interest Expense: Interest expense increased significantly to $4.1 million (from $0.8 million) due to the new $125 million term loan secured in July 2025, which carries an interest rate of approximately 10.2%.
• Tax Impact: Unlike Q1 2025, which included a $29.3 million discrete tax benefit from the release of unrecognized tax benefits (CARES Act), Q1 2026 had no material tax benefit due to the recognition of valuation allowances against deferred tax assets.
• Expense Management: General and administrative expenses decreased by $4.3 million, primarily due to reduced amortization of previously impaired intangible assets and lower rent expenses.

Guidance, Outlook, and Risks

Management Commentary: Management continues to focus on accelerating profitable growth through the Cancer Care Continuum, specifically highlighting the commercial launch of the Precise MRD test and FDA approval of MyChoice CDx. The company believes existing capital resources are sufficient for the next 12 months.

Debt Covenants: The company is subject to a minimum trailing twelve-month revenue test under its Credit Facility, starting at $615.0 million for the period ending December 31, 2025, and increasing quarterly to $974.0 million by December 31, 2029. The company was in compliance with all covenants as of March 31, 2026.

Risks and Contingencies:

• Legal Proceedings: The company is involved in a qui tam lawsuit regarding alleged False Claims Act violations related to physician remuneration. The government has intervened to defend the constitutionality of the statute, but the company is not aware of the complaint until it was unsealed in 2025. No material accrual has been recorded.
• Reimbursement: Ongoing risks related to third-party payor coverage limitations, denials, and reimbursement rate reductions.
• Impairment Risk: Management noted that future declines in share price or revenue could trigger additional impairment charges.

Investor Verification Checklist

• Debt Covenant Compliance: Verify the company's ability to meet the escalating minimum trailing twelve-month revenue covenants ($615M to $974M) over the next several years.
• Impairment Triggers: Monitor share price volatility and market capitalization trends, as these are the primary triggers for further goodwill impairment charges.
• Legal Exposure: Track the status of the qui tam lawsuit and any potential insurance coverage limitations regarding the outcome.
• Prenatal Health Decline: Investigate the drivers behind the 12% volume decrease in the Prenatal Health segment to determine if this is a temporary fluctuation or a structural market shift.
• Cash Burn: Assess the sustainability of the current operating cash burn rate (~$15.7M/quarter) against the $124.4M cash balance and the $75M delayed draw loan availability.